SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-265281
Filing Date
2023-10-27
Accepted
2023-10-27 17:24:30
Documents
14
Period of Report
2023-10-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d537197d8k.htm   iXBRL 8-K 28092
2 EX-10.1 d537197dex101.htm EX-10.1 49929
6 GRAPHIC g537197g1027232551828.jpg GRAPHIC 3398
  Complete submission text file 0001193125-23-265281.txt   221294

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA evlo-20231026.xsd EX-101.SCH 2842
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE evlo-20231026_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE evlo-20231026_pre.xml EX-101.PRE 11253
8 EXTRACTED XBRL INSTANCE DOCUMENT d537197d8k_htm.xml XML 3392
Mailing Address ONE KENDALL SQUARE, 600/700, SUITE 7-201 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE, 600/700, SUITE 7-201 CAMBRIDGE MA 02139 617-577-0300
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 231356452
SIC: 2834 Pharmaceutical Preparations